Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline BioSpaceDenali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) BioSpace Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year. Neuroscience Read full story Post navigation Previous: US launches probe of German ‘underpayment’ for medicinesNext: Japan approves Sanofi’s Sarclisa combo for MM treatment Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
